Skip to main content
. 2023 Feb 13;18(1-2):195–207. doi: 10.1007/s11481-023-10060-3

Fig. 4.

Fig. 4

Effect of alirocumab (Aliro-L,Aliro-M and Aliro-H) on CUMS-induced Changes in a–d Hippocampal PCSK9, TLR-4, NF-κB, and Indolamine 2, 3-Dioxygenase 1 (IDO-1) mRNA expression ef Hippocampal Kynurenine and Tryptophan concentrations; a PCSK9, b TLR-4,, c NF-κB, and d IDO-1 levels, e Kynurenine concentration, f Tryptophan concentration.###P < 0.001 vs. control group and *P < 0.05, **P < 0.01, ***P < 0.001 vs. CUMS group; by one-way ANOVA followed by Bonferroni post-hoc test